Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans (DOXY)

This study has been completed.
Ruth L. Kirschstein National Research Service Award
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Information provided by (Responsible Party):
Karen L. Herbst, University of California, San Diego Identifier:
First received: May 25, 2011
Last updated: May 17, 2013
Last verified: May 2013
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).

Condition Intervention Phase
Type 2 Diabetes
Drug: Doxycycline
Other: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor

Resource links provided by NLM:

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • MMP activity [ Time Frame: Day 1 (baseline) and Day 84 ] [ Designated as safety issue: No ]
    MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9

Secondary Outcome Measures:
  • CRP [ Time Frame: Day 1 (baseline) and Day 84 ] [ Designated as safety issue: No ]
    Measure of global inflammation

Enrollment: 50
Study Start Date: October 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Doxycycline
Participants with DM2 receiving doxycycline 100mg BID
Drug: Doxycycline
generic doxycycline 100mg twice daily
Other Name: Vibramycin
Placebo Comparator: Placebo
Pills prepared identical to doxycycline.
Other: Placebo
Placebo comparator to doxycycline

Detailed Description:

Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical trial conducted in an academic tertiary care center.

Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).

Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also evaluated at D84 after DOX 100mg twice daily or PL.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ambulatory, medically stable, able to give informed consent, and comply with the protocol.
  • Obesity with BMI >30 kg/m2.
  • DM2 for less than 10 years.
  • 7.5% < HA1C < 10%
  • Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)

Exclusion Criteria:

  • Mental states that would preclude complete understanding of the protocol and compliance.
  • Chronic illness such as renal failure (with creatinine clearance <80 ml/min for Specific Aim 2).
  • Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.
  • Nursing mothers.
  • Allergy to tetracyclines.
  • Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01375491

United States, California
University of California San Diego Clinical trials Research Institute
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Ruth L. Kirschstein National Research Service Award
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Principal Investigator: Karen L Herbst, PhD, MD UCSD
  More Information

Responsible Party: Karen L. Herbst, Associate Clinical Professor, University of California, San Diego Identifier: NCT01375491     History of Changes
Other Study ID Numbers: 090395  5M01RR000827  P30DK063491 
Study First Received: May 25, 2011
Last Updated: May 17, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Diego:
insulin resistance

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on October 25, 2016